Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gene Therapy for High Grade Glioma: The Clinical Experience

13 Dec 2022

Abstract excerpt

INTRODUCTION: High-grade gliomas (HGG) are the most common malignant primary brain tumors in adults, with a median survival of ~18 months. The standard of care (SOC) is maximal safe surgical resection, and radiation therapy with concurrent and adjuvant temozolomide. This protocol remains unchanged since 2005, even though HGG median survival has marginally improved. AREAS COVERED: Gene therapy was developed as a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Research and Treatments
Share to Glioma Diagnosis and Treatment
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36510843
DOI: 10.1080/14712598.2022.2157718

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gene Therapy for High Grade Glioma: The Clinical ExperiencePMID 36510843Read ↗

Gene Therapy for High-Grade GliomaSemantic proximity Read ↗

Against the Resilience of High-Grade Gliomas: Gene Therapies (Part II)Semantic proximity Read ↗

Virus-Based Therapies for the Treatment of Recurrent High-Grade GliomaSemantic proximity Read ↗

Oncolytic herpes simplex viruses for the treatment of glioma and targeting glioblastoma stem-like cellsSemantic proximity Read ↗

Strategies in Gene Therapy for GlioblastomaSemantic proximity Read ↗

A non-randomized, open-label, dose-finding, first-in-human trial of combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: transgene expression persists up to 17 months post-vector injectionSemantic proximity Read ↗

Treatment of Adult Lower-Grade Glioma in the Era of Genomic Medicine.Semantic proximity Read ↗

Gene therapy in glioblastoma multiforme: Can it be a role changer?Semantic proximity Read ↗

Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas.Semantic proximity Read ↗

Combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: a phase 1, first-in-human trialSemantic proximity Read ↗

Glioma targeted therapy: insight into future of molecular approaches.Semantic proximity Read ↗

Adenovirus Mediated Herpes Simplex Virus-Thymidine Kinase/Ganciclovir Gene Therapy for Resectable Malignant GliomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.